

Jochen Währle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7140607/publications.pdf>

Version: 2024-02-01

94
papers

4,122
citations

186265

28
h-index

123424

61
g-index

94
all docs

94
docs citations

94
times ranked

4866
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS121011325.	3.9	15
2	Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, 101161CIRCINTERVENTIONS121011569.	3.9	17
3	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome Undergoing Complex Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010565.	3.9	4
4	Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1789-1798.	2.9	22
5	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndrome in Relation to Estimated Glomerular Filtration Rate. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1857-1866.	2.9	9
6	Evaluation of Cerebral Thromboembolism After Transcatheter Aortic Valve Replacement (EARTH TAVR): A Serial Magnetic Resonance Imaging Evaluation as Substudy of the GALILEO Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e011074.	3.9	1
7	Twelve-month clinical outcomes in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: insights from the ISAR-REACT 5 trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 1117-1124.	1.0	5
8	A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2020, 382, 120-129.	27.0	362
9	Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. <i>Lancet</i> , The, 2020, 396, 1504-1510.	13.7	96
10	Impact of coronary calcification on outcomes after ABSORB scaffold implantation: insights from the GABI-R registry. <i>Coronary Artery Disease</i> , 2020, 31, 578-585.	0.7	1
11	Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2238-2247.	2.9	27
12	Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes. <i>Annals of Internal Medicine</i> , 2020, 173, 436-444.	3.9	44
13	Ticagrelor or Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2020, 142, 2329-2337.	1.6	26
14	Ticagrelor or Prasugrel in Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2436-2446.	2.8	41
15	Insights on Embolic Protection, Repositioning, and Stroke: A Subanalysis of the RESPOND Study. <i>Journal of Interventional Cardiology</i> , 2020, 2020, 1-7.	1.2	7
16	Risk factors for permanent pacemaker implantation in patients receiving a balloon-expandable transcatheter aortic valve prosthesis. <i>Heart and Vessels</i> , 2020, 35, 1735-1745.	1.2	3
17	Two year efficacy and safety of small versus large ABSORB bioresorbable vascular scaffolds of 18mm device length: A subgroup analysis of the German-Austrian ABSORB RegistRy (GABI-R). <i>IJC Heart and Vasculature</i> , 2020, 27, 100501.	1.1	0
18	Predictors of left ventricular reverse remodeling after percutaneous therapy for mitral regurgitation with the MitraClip system. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 687-697.	1.7	7

#	ARTICLE	IF	CITATIONS
19	A Longitudinal Echocardiographic Analysis of Patients Treated Using the Repositionable and Fully Retrievable Lotus Valve: A Sub-Analysis of the RESPOND Study. <i>Structural Heart</i> , 2020, 4, 26-33.	0.6	1
20	Drug-coated balloon versus drug-eluting stent in small coronary artery lesions: angiographic analysis from the BASKET-SMALL 2 trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1114-1124.	3.3	18
21	Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2019, 381, 1524-1534.	27.0	543
22	Clinical results of bioresorbable drug-eluting scaffolds in short and long coronary artery lesions using the PSP technique. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 22.	1.7	1
23	Hybrid Coronary Percutaneous Treatment with Metallic Stents and Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-Years Results from the GABI-R Registry. <i>Journal of Clinical Medicine</i> , 2019, 8, 767.	2.4	0
24	Transcatheter Aortic Valve Replacement With Next-Generation Self-Expanding Devices. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 433-443.	2.9	59
25	Clinical outcomes of the Lotus Valve in patients with bicuspid aortic valve stenosis: An analysis from the RESPOND study. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1116-1123.	1.7	15
26	Predictors of rehospitalization after percutaneous edge-to-edge mitral valve repair by MitraClip implantation. <i>European Journal of Heart Failure</i> , 2019, 21, 182-192.	7.1	39
27	Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis. <i>European Heart Journal</i> , 2019, 40, 1334-1340.	2.2	77
28	Use of a Repositionable and Fully Retrievable Aortic Valve in Routine Clinical Practice. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 38-49.	2.9	21
29	Long-term clinical outcome of persistent left bundle branch block after transfemoral aortic valve implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 538-544.	1.7	4
30	Impact of Repositioning During Transcatheter Aortic Valve Replacement on Embolized Debris. <i>Journal of Invasive Cardiology</i> , 2019, 31, 282-288.	0.4	5
31	Predictors of early scaffold thrombosis. <i>Coronary Artery Disease</i> , 2018, 29, 389-396.	0.7	6
32	Importance of Contrast Aortography With Lotus Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 119-128.	2.9	14
33	Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2. <i>Clinical Cardiology</i> , 2018, 41, 569-575.	1.8	13
34	New generation devices for transfemoral transcatheter aortic valve replacement are superior compared with last generation devices with respect to VARC-2 outcome. <i>Cardiovascular Intervention and Therapeutics</i> , 2018, 33, 247-255.	2.3	21
35	Longitudinal strain assessed by cardiac magnetic resonance correlates to hemodynamic findings in patients with severe aortic stenosis and predicts positive remodeling after transcatheter aortic valve replacement. <i>Clinical Research in Cardiology</i> , 2018, 107, 20-29.	3.3	24
36	Transfemoral aortic valve implantation is more successful with the Edwards Sapien 3 compared with the Edwards XT for the treatment of symptomatic severe aortic stenosis. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 470-479.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Atrial Fibrillation Predicts Long-Term Outcome after Transcatheter Edge-to-Edge Mitral Valve Repair by MitraClip Implantation. <i>Biomolecules</i> , 2018, 8, 152.	4.0	18
38	Intra-aortic balloon counterpulsation pump in heart failure patients during MitraClip implantation: A propensity score matched analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 1433-1438.	1.7	4
39	Significant Differences in Debris Captured by the Sentinel Dual-Filter Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement Among Different Valve Types. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1683-1693.	2.9	34
40	Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. <i>Lancet</i> , The, 2018, 392, 849-856.	13.7	263
41	Author's reply. <i>Journal of Cardiology</i> , 2018, 71, 598.	1.9	0
42	Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 66-74.	2.9	114
43	First experience with the Watchman FLX occluder for percutaneous left atrial appendage closure. <i>Cardiovascular Revascularization Medicine</i> , 2017, 18, 512-516.	0.8	8
44	Bioresorbable scaffolds compared with everolimus-eluting stents for the treatment of chronic coronary total occlusion. <i>Coronary Artery Disease</i> , 2017, 28, 120-125.	0.7	6
45	Outcome With the Repositionable and Retrievable Boston Scientific Lotus Valve Compared With the Balloon-Expandable Edwards Sapien 3 Valve in Patients Undergoing Transfemoral Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	17
46	Predictors for permanent pacemaker implantation in patients undergoing transfemoral aortic valve implantation with the Edwards Sapien 3 valve. <i>Clinical Research in Cardiology</i> , 2017, 106, 590-597.	3.3	45
47	Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement Significantly Reduces Death and Stroke Compared With Unprotected Procedures. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2297-2303.	2.9	136
48	Predictors of permanent pacemaker implantation after transfemoral aortic valve implantation with the Lotus valve. <i>American Heart Journal</i> , 2017, 192, 57-63.	2.7	10
49	Safety and efficacy of a repositionable and fully retrievable aortic valve used in routine clinical practice: the RESPOND Study. <i>European Heart Journal</i> , 2017, 38, 3359-3366.	2.2	68
50	The balloon-expandable Edwards Sapien 3 valve is superior to the self-expanding Medtronic CoreValve in patients with severe aortic stenosis undergoing transfemoral aortic valve implantation. <i>Journal of Cardiology</i> , 2017, 69, 877-882.	1.9	17
51	Outcome of Patients with Mixed Aortic Valve Disease Undergoing Transfemoral Aortic Valve Replacement. <i>Structural Heart</i> , 2017, 1, 162-167.	0.6	11
52	Long-term clinical results of bioresorbable absorb scaffolds using the PSP technique in patients with and without diabetes. <i>Journal of Interventional Cardiology</i> , 2017, 30, 325-330.	1.2	10
53	Percutaneous Mitral Valve Repair With the MitraClip in Primary Compared With Secondary Mitral Valve Regurgitation Using the Mitral Valve Academic Research Consortium Criteria. <i>Journal of Invasive Cardiology</i> , 2017, 29, 145-150.	0.4	6
54	Transfemoral aortic valve implantation in pure native aortic valve insufficiency using the repositionable and retrievable lotus valve. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 993-995.	1.7	27

#	ARTICLE	IF	CITATIONS
55	Zotarolimus compared with everolimus eluting stents—angiographic and clinical results after recanalization of true coronary chronic total occlusions. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 18-23.	1.7	7
56	Impact of suture mediated femoral access site closure with the Prostar XL compared to the ProGlide system on outcome in transfemoral aortic valve implantation. <i>International Journal of Cardiology</i> , 2016, 223, 564-567.	1.7	34
57	Transfemoral valve-in-valve implantation for degenerated bioprosthetic aortic valves using the new balloon-expandable Edwards Sapien 3 valve. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 636-643.	1.7	10
58	Non-contrast-enhanced magnetic resonance angiography is equal to contrast-enhanced multislice computed tomography for correct aortic sizing before transcatheter aortic valve implantation. <i>Clinical Research in Cardiology</i> , 2016, 105, 273-278.	3.3	20
59	Bicuspid Aortic Stenosis Treated With the Repositionable and Retrievable Lotus Valve. <i>Canadian Journal of Cardiology</i> , 2016, 32, 135.e17-135.e19.	1.7	17
60	Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk. <i>Clinical Research in Cardiology</i> , 2016, 105, 225-229.	3.3	19
61	Evaluation of the short- and long-term safety and therapy outcomes of the everolimus-eluting bioresorbable vascular scaffold system in patients with coronary artery stenosis: Rationale and design of the German—Austrian ABSORB RegIstRy (GABI-R). <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 34-37.	0.8	24
62	Transfemoral Aortic Valve Implantation with the New Edwards Sapien 3 Valve for Treatment of Severe Aortic Stenosis—Impact of Valve Size in a Single Center Experience. <i>PLoS ONE</i> , 2016, 11, e0151247.	2.5	22
63	Bioresorbable polymer sirolimus-eluting coronary stent compared with permanent polymer everolimus-eluting coronary stent implantation for treatment of small vessel coronary artery disease: CENTURY II trial. <i>EuroIntervention</i> , 2016, 12, e167-e174.	3.2	24
64	Transfemoral aortic valve implantation with the repositionable Lotus valve for treatment of patients with symptomatic severe aortic stenosis: results from a single-centre experience. <i>EuroIntervention</i> , 2016, 12, 760-767.	3.2	14
65	Transfemoral aortic valve implantation with the repositionable Lotus valve compared with the balloon-expandable Edwards Sapien 3 valve. <i>International Journal of Cardiology</i> , 2015, 195, 171-175.	1.7	44
66	Improvement of regional and global left ventricular function in magnetic resonance imaging after recanalization of true coronary chronic total occlusions. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 228-232.	0.8	15
67	Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. <i>EuroIntervention</i> , 2015, 11, 149-156.	3.2	51
68	Comprehensive Prognosis Assessment by CMR Imaging After ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1217-1226.	2.8	314
69	Impact of Long-Term Statin Pretreatment on Myocardial Damage in ST Elevation Myocardial Infarction (from the AIDA STEMI CMR Substudy). <i>American Journal of Cardiology</i> , 2014, 114, 503-509.	1.6	11
70	Impact of cell number and microvascular obstruction in patients with bone-marrow derived cell therapy: final results from the randomized, double-blind, placebo controlled intracoronary Stem Cell therapy in patients with Acute Myocardial Infarction (SCAMI) trial. <i>Clinical Research in Cardiology</i> , 2013, 102, 765-770.	3.3	51
71	Impact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention of the Left Anterior Descending Artery. <i>American Journal of Cardiology</i> , 2013, 112, 753-760.	1.6	12
72	Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 793-799.	1.7	38

#	ARTICLE	IF	CITATIONS
73	Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. <i>Lancet</i> , The, 2012, 379, 923-931.	13.7	199
74	PFO closure and Cryptogenic Stroke (PRECISE) registry: a multi-center, international registry. <i>Clinical Research in Cardiology</i> , 2012, 101, 787-793.	3.3	16
75	SeQuent Please World Wide Registry. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1733-1738.	2.8	186
76	Drug-Coated Balloons for Coronary and Peripheral Interventional Procedures. <i>Current Cardiology Reports</i> , 2012, 14, 635-641.	2.9	21
77	Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: The horizons-AMI CMRI substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 1083-1089.	1.7	23
78	Everolimus-eluting stents for treatment of chronic total coronary occlusions. <i>Clinical Research in Cardiology</i> , 2012, 101, 23-28.	3.3	19
79	Prospective randomised trial evaluating a paclitaxel-coated balloon in patients treated with endothelial progenitor cell capturing stents for de novo coronary artery disease. <i>Heart</i> , 2011, 97, 1338-1342.	2.9	73
80	Characterization of patients with acute chest pain using cardiac magnetic resonance imaging. <i>Clinical Research in Cardiology Supplements</i> , 2010, 5, 63-69.	2.0	2
81	Results of Intracoronary Stem Cell Therapy After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2010, 105, 804-812.	1.6	102
82	Impact of Transfer for Primary Percutaneous Coronary Intervention on Survival and Clinical Outcomes (from the HORIZONS-AMI Trial). <i>American Journal of Cardiology</i> , 2010, 106, 1218-1224.	1.6	15
83	Prevalence of Myocardial Scar in Patients With Cryptogenic Cerebral Ischemic Events and Patent Foramen Ovale. <i>JACC: Cardiovascular Imaging</i> , 2010, 3, 833-839.	5.3	26
84	Impact of Percutaneous Device Implantation for Closure of Patent Foramen Ovale on Valve Insufficiencies. <i>Circulation</i> , 2009, 119, 3002-3008.	1.6	19
85	Carbon-coated Stents in Patients with Acute Coronary Syndromes. <i>Clinical Cardiology</i> , 2009, 32, E1-6.	1.8	8
86	Angiographic results of the cobalt chromium Vision and Mini-Vision stents. <i>Canadian Journal of Cardiology</i> , 2009, 25, 581-584.	1.7	7
87	Impact of pioglitazone on coronary endothelial function in non-diabetic patients with coronary artery disease. <i>Clinical Research in Cardiology</i> , 2008, 97, 726-733.	3.3	16
88	Intracoronary application of abciximab in patients with ST-elevation myocardial infarction. <i>EuroIntervention</i> , 2008, 3, 465-469.	3.2	16
89	Comparison of the slow-release polymerbased paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions. <i>Clinical Research in Cardiology</i> , 2007, 96, 70-76.	3.3	51
90	Closure of patent foramen ovale after cryptogenic stroke. <i>Lancet</i> , The, 2006, 368, 350-352.	13.7	60

#	ARTICLE	IF	CITATIONS
91	Repeat intracoronary ^{188}Re -brachytherapy using a rhenium-188-filled balloon catheter for recurrent restenosis in patients who failed intracoronary radiation therapy. <i>Cardiovascular Revascularization Medicine</i> , 2006, 7, 2-6.	0.8	4
92	Intracoronary ^{188}Re -brachytherapy using a rhenium-188 filled balloon catheter in restenotic lesions of native coronary arteries and venous bypass grafts. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1314-1320.	6.4	7
93	Myocardial Perfusion Reserve in Cardiovascular Magnetic Resonance: Correlation to Coronary Microvascular Dysfunction. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2006, 8, 781-787.	3.3	49
94	Reduction of Major Adverse Cardiac Events With Intracoronary Compared With Intravenous Bolus Application of Abciximab in Patients With Acute Myocardial Infarction or Unstable Angina Undergoing Coronary Angioplasty. <i>Circulation</i> , 2003, 107, 1840-1843.	1.6	134